Neoadjuvant chemotherapy followed by surgery and versus surgery and for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma: ECOG-ACRIN EA3163
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2025.
All research outputs
#23,461,750
of 34,560,573 outputs
Outputs from Clinical Cancer Research
#15,384
of 17,697 outputs
Outputs of similar age
#172,913
of 361,819 outputs
Outputs of similar age from Clinical Cancer Research
#64
of 121 outputs
Altmetric has tracked 34,560,573 research outputs across all sources so far. This one is in the 30th percentile – i.e., 30% of other outputs scored the same or lower than it.
So far Altmetric has tracked 17,697 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.4. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,819 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 121 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
